Author
@FiercePharma FiercePharma
Pharma trade outlet relaying FDA, deal, and exec-move newsflow in real time
Institutional pharma/biopharma journalism: breaks and relays
trader score
-1.09
hit rate
53%
mean α
-0.44%
signals 14d
5
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 19 scored bets: 53% hit rate, -0.44% mean alpha, trader score -1.09. Their last-14d mentions, direction-adjusted, have moved +0.8% since posting (mean over 1 mentions with price data).
Recent signals5receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-08-28 | LLY | @FiercePharma | +0.45 | Reports Lilly's oral GLP-1 prescriptions crossing 40,000. | — | tweet ↗ |
| 2026-08-25 | · | @FiercePharma | · | FDA approved Jazz's Ziihera for stomach cancer. | · | tweet ↗ |
| 2026-08-18 | · | @FiercePharma | · | CSL projections and immunoglobulin growth outlook drove a 17% share-price gain. | · | tweet ↗ |
| 2026-08-18 | EYPT | @FiercePharma | -0.70 | EyePoint shares plunge after Duravyu stumbled in a phase 3 trial. | · | tweet ↗ |
| 2026-08-18 | BMY | @FiercePharma | +0.35 | A bispecific ADC met its lung-cancer trial goal, supporting BMS's global testing case. | +0.8% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.